1. Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome
Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S., J. Thomas Grayston, M.D., Brent Muhlestein, M.D., Robert P. Giugliano, M.D., Richard Cairns, M.Sc., Allan M. Skene, Ph.D. and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
N Engl J Med
Volume 352;16:
April 21, 2005

2. Study Overview
Studies have suggested that infection with Chlamydia pneumoniae may have a role in the pathogenesis of coronary artery disease
This study casts doubt on the idea, since two years of treatment with gatifloxacin, an antibiotic with bactericidal activity against C
pneumoniae, had no beneficial effect on clinical outcomes
This study complements the results of the study by Grayston et al
reported in this issue of the Journal, which led to a similar conclusion

3. Numbers of Patients Who Were Randomly Assigned to a Treatment Group, Who Started the Assigned Treatment, and Who Discontinued Treatment or Were Lost to Follow-up
Cannon, C. et al. N Engl J Med 2005;352:

4. Baseline Characteristics of the Patients
Cannon, C. et al. N Engl J Med 2005;352:

5. Kaplan-Meier Estimates of Events over Time among Patients Treated with Gatifloxacin or Placebo
Cannon, C. et al. N Engl J Med 2005;352:

6. Risk Reduction for Death or a Major Cardiovascular Event and Event Rates at Two Years
Cannon, C. et al. N Engl J Med 2005;352:

7. Hazard Ratios for Death or a Major Cardiovascular Event, with Two-Year Event Rates, According to Baseline Characteristics
Cannon, C. et al. N Engl J Med 2005;352:

8. Conclusions
Despite long-term treatment with a bactericidal antibiotic effective against C
pneumoniae, no reduction in the rate of cardiovascular events was observed